Scancell Share Discussion Threads

[inanaco] 20/11/2024 11:59

Burbles

......... hearsay



how many dose per patient ?

how many trials are currently running with how many patients ?

can they use German manufacturing capacity ?

who owns this UK capacity ?

[2tyke] 20/11/2024 11:57

It depends what information you consider useless inane...
I'm only interested in stock prices.
Therefore every single piece of info on this bb is useless ....as has been proved over many years !

[bermudashorts] 20/11/2024 11:52

What rumuor?

[inanaco] 20/11/2024 11:48

Bermudashorts

Posts: 12,806

Price: 14.75

No Opinion

RE: Strengths of SCIB1/iSCIB1+Today 11:12
Another really useful and informative post Burble - thanks.

--------------------------------------------------------------------

A useless bit of information put out as a rumour ....

[inanaco] 20/11/2024 11:43

BioNtech

Fully owned state-of-the-art manufacturing facilities for just-in-time delivery and scalable production
To successfully bring individualized immunotherapies to patients and vaccines to people around the world, it is crucial to have in-house manufacturing capabilities. We have several manufacturing sites ""capable of developing"" fully automated production processes for on-demand production of our therapies and vaccines.


i should study the market rather than listen to "chit chat" from burble

[inanaco] 20/11/2024 11:35

marcus ........ why would you spend absolute millions building capacity without approval with the added cost of running and maintaining idle equipment ... not only that it might go obsolete while you wait because of the speed of development

once you have identified the design of the production line .... built and tested

you replicate ... on approval

[inanaco] 20/11/2024 11:30

well somebody chased the Rainbow which saved your life Lozan .... now do us all a favour and .................

[marcusl2] 20/11/2024 11:28

But they are likely to be approved therefore it is relevant Inan.

[inanaco] 20/11/2024 11:28

I did not know but with some patients treated with immunotherapy they get benign cysts around the site of the cancer .... which on a scan appears as cancer ... but the cancer has gone .... so some are diagnosed as stable but actually they are cancer free

which is interesting if you recall modi1 and macmillian

[inanaco] 20/11/2024 11:19

as i have already stated marcus ... Non are approved yet, so its a post of no value

because its for clinical trial use only

its always being the case that SCIB1/modi will out compete a Personal vaccine if it achieves the required efficacy

because of the capital cost of setting up a manufacturing site to deal with MRNA they have to make sure that they have the proven efficacy and t that may be the stumbling block, not the fact that it will work but can they get it more effective than off the shelf to warrant this outlay ...

lindy has stated the failure occurs very early in the treatment cycle, it may be possible to look at those patients cancers on an individual basis, but if they fail Scib1 and checkpoints ... i suspect a personal vaccine will also find it very hard to make head way because there immune systems are just not up to it

[inanaco] 20/11/2024 11:06

ask the cancer patients Lozan

its called PFS

i assume the manufacturer of your stent had to get it approved ...

I wonder how much time they gave you as a bonus ?

along with the multiple tablets you take every day to control "stress" so that you don't stroke out

all got approval ...

how much would you pay to stay alive ?

[inanaco] 20/11/2024 11:01

Put Burbles 3000 dose manufacture capacity into context

Non are approved yet

[chilltime] 20/11/2024 10:01

Genentech/Roche as it’s right up their street being the pioneers of antibodies fighting cancer. Plus the Tecentriq point on SC124

It could be someone entirely different.

Genmab going to phase 1, so clearly the Glymab gave preclinical results that they like.

SC134 excellent pre clinical.

So it’s stacking up that the glycans approach is producing promising early results.

Given that the platform can produce many more Glymabs it’s a potentially very hogh value platform.

So the £600m point by MT is probably a bargain given the potential.

[markingtime] 20/11/2024 08:12

I know all that. Hence my comment stands as written.Note that the GenMab deal has an update due in December at approximately the same time as the option for the new deal with the anonymous counterparty expires. Entirely possible that a broader deal is also under discussion - and not necessarily with "the usual suspects".

[chilltime] 20/11/2024 07:29

MT

Genmab is a licensing deal

The anon one is an evaluation with an option to license.

The article says collaboration, a major biotech.

It could be the evaluation has evolved into further cosying up. Typically proteins are a target, sugars are a new approach, pretty much dominated by Scancell through Glymabs.

Cells have sugar types on them and they change on cancerous cells, which are largely absent on healthy cells.

So the change becomes the target. Scancell know how to target them, others don’t.

There is a big pool of potential antibodies that can come out of that platform

[markingtime] 20/11/2024 04:47

Interesting thought re Genentech. I'm wondering if such a sub of a major could collaborate on a joint venture with the Glymab platform, effectively buying into Scancell's technology by providing cash and ongoing know-how in related areas?https://www.gene.com/partners/partner-with-usSimilarly, I wonder about working with Google Deepmind......As we know, there are a lot of possible options - but which is the best way forward?

[2tyke] 19/11/2024 21:07

I don't think chilltime will mind Nigel.
And he can't really help you...you're well beyond that !

[nigelpm] 19/11/2024 20:33

Another idiot filtered. Getting to be a habit.

[2tyke] 19/11/2024 20:28

That's right....if there was any feed-back loop from company news into the stock price you wouldn't always be wrong on here would you ???